Innovation Labs @ TMC set to launch for early-stage life science startups

moving in

Innovation Labs @ TMC will open next year at the TMC Innovation Factory. Photo courtesy JLABS.

The Texas Medical Center will launch its new Innovation Labs @ TMC in January 2026 to better support life science startups working within the innovation hub.

The 34,000-square-foot space, located in the TMC Innovation Factory at 2450 Holcombe Blvd., will feature labs and life science offices and will be managed by TMC. The space was previously occupied by Johnson & Johnson's JLABS @TMC, a representative from TMC tells InnovationMap. JLABS will officially vacate the space in January.

TMC shares that the expansion will allow it to "open its doors to a wider range of life science visionaries," including those in the TMC BioBridge program and Innovation Factory residents. It will also allow TMC to better integrate with the Innovation Factory's offerings, such as the TMC Health Tech accelerator, TMC Center for Device Innovation and TMC Venture Fund.

“We have witnessed an incredible demand for life science space, not only at the TMC Innovation Factory, but also on the TMC Helix Park research campus,” William McKeon, president and CEO of the TMC, said in a news release. “Innovation Labs @ TMC enables us to meet this rising demand and continue reshaping how early-stage life science companies grow, connect, and thrive.”

“By bringing together top talent, cutting-edge research, and industry access in one central hub, we can continue to advance Houston’s life science ecosystem," he continued.

The TMC Innovation Factory has hosted 450 early-stage ventures since it launched in 2015. JLABS first opened in the space in 2016 with the goal of helping health care startups commercialize.

From Your Site Articles
Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

AI-optimized health startup with HQ in Houston takes its tech to the next level with new partner

ending cancer

Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

"Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

"I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

Houston can expect the new vaccine in the next week. WPA Pool / Getty Images

Here's when Houston can expect the Johnson & Johnson COVID-19 vaccine

coming soon

Texas can expect to receive the first 200,000 doses of the coveted Johnson & Johnson COVID-19 vaccine this week. The company announced that it has started the rollout process on March 1 — after the FDA approved its Emergency Use Authorization.

The Center for Disease Control gave the developer, Janssen Pharmaceutical, the final greenlight Sunday, February 28.

What does that mean for Houston? Mayor Sylvester Turner said the Houston Health Department is also anticipated to be on the list to receive Johnson & Johnson doses within the next seven days.

"That will be a game changer," Turner said at an event on February 28 afternoon. "There will be more vaccines available in a shorter period of time. We anticipate that we will probably get a shipment in sometime this week that will add to the Pfizer [doses] that we are using at NRG."

Turner said other clinics with the Houston Health Department have been administering the Moderna vaccine.

The Johnson & Johnson vaccine does have noticeable differences from the Pfizer and Moderna vaccines, experts said.

The MRNA vaccines each require two shots which are usually delivered weeks apart and stored in freezers. The Johnson & Johnson vaccine is a single shot that can be stored in a refrigerator for up to three months at 35 to 46 degrees.

However, Johnson & Johnson does not have as much of the COVID-19 vaccine produced as originally anticipated. ABC13 confirmed 3.9 million doses will be shipped out across the country this week. Johnson & Johnson announced roughly an additional 16 million doses by the end of the month.

"In the next few weeks, it won't have much of any impact because they only have at least three or four million doses available, and that's disappointing news," says Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. "In the longer term, over the next few months, it's really important because we need a greater vaccine supply. We are not going to get there with the two MRNA vaccines. We need probably up to five different vaccines in order to vaccinate the American people."

Recently, there has been a decline in COVID-19 hospitalizations and COVID-19 cases reported statewide. As of Sunday, about 5,700 Texans are in the hospital due to COVID-19, which is half the number of hospitalization in the beginning of the month.

Infectious disease epidemiologist Dr. Catherine Troisi says it's important for people to not let their guard down and that people should get tested if they have been in a high-exposure situation, or if they have been in direct contact with someone who has tested positive.

"Get vaccinated, don't worry about what vaccine it is," Dr. Troisi notes. "It's true that unfortunately there are not as many doses right now of the Johnson & Johnson vaccine as we have hoped, but the company is saying that by the end of June, they will have a 100 million doses, and that's into 100 million people because you don't need two doses.

"So, we expect to have 600 million doses of the other two vaccines, that's 300 million people," she continues. "That should be enough for everyone who wants the vaccine to be able to get it. With one caveat and that is as of right now we do not have a vaccine for children under age 16. Those trials are going on, hopefully as we go throughout the year there will be a vaccine licensed to 12 year-olds and then maybe going down to 8 years or older."

For more details on the Johnson & Johnson vaccine rollout, visit the FDA's website.

---

This article originally ran on CultureMap. For more on this story, visit our news partner ABC13.

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

TMC names former JLABS leader as the director of the Innovation Institute

taking control

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice lands $15M U.S. Army award to launch next-gen wireless research center

defense funding

The U.S. Army Research Office has awarded Rice University $15 million to establish a new center for next-generation sensing and communications.

The five-year research center—dubbed the Center for Large Aperture Secure Sensing, Imaging and Communications (CLASSIC)—will unite researchers from universities and national laboratories to develop advanced antenna technologies for future wireless systems. Edward Knightly, the Sheafor-Lindsay Professor of Electrical and Computer Engineering at Rice, will lead the center that “combines expertise in wireless networking, antennas, radar, artificial intelligence, circuits and physics to address growing demands on wireless systems,” according to Rice.

“The challenges we’re tackling require advances that span physics, hardware, communications and computing," Knightly said in a news release. “By combining those strengths in a single center, we can accelerate the development and demonstration of technologies that would not be possible through individual efforts alone.”

Joining Knightly will be Ashutosh Sabharwal of Rice, Sensen Li of the University of Texas at Austin, Hou-Tong Chen of Los Alamos National Laboratory, Danijela Cabric of UCLA, Josep M. Jornet and Tommaso Melodia of Northeastern University, Daniel M. Mittleman of Brown University, and Willie Padilla of Duke University.

Industry partners include Booz Allen Hamilton, Intel, Keysight, Lockheed Martin, MITRE, Northrop Grumman, Qualcomm and Raytheon.

CLASSIC researchers will investigate how large-scale antenna arrays (ELSAAs) can expand the capabilities of wireless systems where technology is limited.

ELSAAs use thousands of coordinated antenna elements to direct radio waves. Researchers aim to develop ways to use the technology to help maintain steady communication when signals are blocked or disrupted and to detect and generate detailed images of concealed objects.

Along with ELSAAs, the center will work to develop sensing techniques for threat detection, study wireless jamming and build resilient high-speed wireless networks. Researchers will ultimately validate the technology in labs and via drone-based field trials.

CLASSIC will also work on developing an AI-driven modeling framework that will simulate complex electromagnetic environments in real time.

“This award demonstrates Rice’s leadership in tackling complex national research challenges through collaboration across disciplines and institutions,” David Sholl, executive vice president for research at Rice, added in the release.

UH scores $18M NIH grant for chronic disease research

research funding

The University of Houston has received a coveted $18.8 million grant from the National Institutes of Health to launch a program to address the root causes of chronic disease.

Only 22 institutions nationwide receive this NIH award, and the 5-year process aligns with the newly established UH Health’s mission to expand healthcare innovations in Texas and beyond. The initiative will be housed in the UH Population Health department.

"This generous funding allows us to directly confront the root causes of chronic illness that place a heavy burden on so many families," Dr. Jonathan McCullers, vice president for health affairs at UH, said in a news release. "With the recent launch of UH Health, we have an unprecedented opportunity to translate scientific discovery into healthier outcomes for our communities by bringing together experts from across the university to improve health where it matters most.”

Through the program, UH researchers from different areas of expertise will work together to address the challenges of chronic illness by looking at biological, social and behavioral factors.

According to the university, chronic diseases like heart disease, diabetes, strokes and others are the leading cause of illness, disability and death in the U.S. They account for 90 percent of the nation’s $5.3 trillion in annual healthcare spending.

Bettina Beech, chief of population health and translational science at UH, serves as principal investigator for the program.

“Chronic disease management largely happens during the 8,700 hours each year that people are not visiting their healthcare provider,” Beech added in the news release. “While healthcare is indispensable, it only accounts for 20 percent of how health is created — genetics accounts for another 10 percent, and the other 70 percent is determined by behavior, social conditions and environment.”

With the funds from the grant, UH will also be able to expand research infrastructure, add to community partnerships, support complementary research, and invest in early-career investigators, according to the news release. UH also aims to develop solutions that could help ease the economic burden of chronic disease.

Report: Where Texas ranks among best and worst states to live in 2026

Texas Talk

After earning its worst-ever ranking last year, Texas has improved slightly on an evaluation of the best states to live, but it's still at the bottom of the pack.

Each year, WalletHub's analysts compare all 50 states using 51 livability metrics to measure their affordability, economy, education and health, quality of life, and safety. Factors that were weighed include the cost of living, homeownership rates, population and income growth rates, wealth gaps, public school system quality, road quality, crime rates, and many others.

The Lone Star State landed at No. 36 in 2026, making it the 15th worth state to live right now. That's on par with its 2024 ranking, and it's a two-spot improvement over its 2025 performance.

While Texas residents can brag about living in a state with the No. 1 highest number of restaurants per capita and the 7th best quality of life in the country, that's about it. Texas earned middling-to-poor scores among the four remaining livability rankings: safety (No. 33), affordability (No. 35), economy (No. 37), and education and health (No. 40).

Here's how Texas fared in other nationwide rankings in the study:

  • No. 27 – Income Growth
  • No. 30 – Housing Costs
  • No. 39 – Percentage of Population in Poverty
  • No. 42 – Percentage of Adults in Fair or Poor Health
  • No. 46 – Homeownership Rate
  • No. 49 – Percentage of Population Aged 25 and Older with a High School Diploma or Higher
  • No. 48 – Average Weekly Work Hours
  • No. 50 – Percentage of Insured Population

Texas has a lot of work to do to improve its livability for all of its residents, but especially for women, according to several other 2026 WalletHub studies. Texas is the fourth-worst state for women, the ninth-worst state for working mothers, and the seventh-worst place to have a baby based on limited access to maternal and pediatric healthcare.

At the very bottom of the report is New Mexico, ranking 50th overall, with Louisiana (No. 49), Mississippi (No. 48), Alaska (No. 47), and Arkansas (No. 46) rounding out the bottom five.

After holding on as the No. 1 best state to live for a few years in a row, Massachusetts now ranks No. 4 and was overtaken by Idaho (No. 1), New Jersey (No. 2), and Wisconsin (No. 3). New Hampshire rounds out the top five best states to live.

WalletHub's top 10 best states to live in 2026 are:

  • No. 1 – Idaho
  • No. 2 – New Jersey
  • No. 3 – Wisconsin
  • No. 4 – Massachusetts
  • No. 5 – New Hampshire
  • No. 6 – Wyoming
  • No. 7 – Utah
  • No. 8 – Minnesota
  • No. 9 – Pennsylvania
  • No. 10 – Florida
---

This article originally appeared on CultureMap.com.

View All Listings